Emerging theragnostic radionuclide applications for hepatocellular carcinoma

Frontiers in Nuclear Medicine

Nuclear Medicine

A. A. Gutta¹  X. Khuzwayo¹  N. E. Nyakale²  L. Harry³  M. M. Sathekge⁴  C. Aldous⁵ 

[1] Department of Nuclear Medicine, Sefako Makgatho Health Sciences University, Dr George Mukhari Academic Hospital, Pretoria, South Africa;Department of Nuclear Medicine, Sefako Makgatho Health Sciences University, Dr George Mukhari Academic Hospital, Pretoria, South Africa;Department of Nuclear Medicine, University of Kwa-Zulu Natal, Durban, South Africa;Department of Nuclear Medicine, University of Kwa-Zulu Natal, Durban, South Africa;Department of Nuclear Medicine, University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa;Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa;School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa;

关键词: transarterial radionuclide therapy;    radioembolization;    hepatocellular carcinoma;    prostate specific membrane antigen;    fibroblast activation protein inhibitors;    lipiodol;    microspheres;    theragnostics;   

DOI  :  10.3389/fnume.2023.1210982

 received in 2023-04-23, accepted in 2023-09-29,  发布年份 2023

来源: Frontiers

【 摘 要 】

Hepatocellular carcinoma (HCC) is a major global health problem. Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic in HCC involves the use of imaging techniques to diagnose the cancer and assess its characteristics, such as size, location, and extent of spread. Theragnostic involves the use of molecular and genetic tests to identify specific biomarkers that can help guide treatment decisions and post treatment assess the dosimetry and localization of the treatment, thus assisting to guide future treatment. This can be done through either positron emission tomography (PET) scanning or single photon emission tomography (SPECT) using radiolabelled tracers that target specific molecules expressed by HCC cells or radioembolization. This technique can help identify the location and extent of the cancer, as well as provide information on the tumour's metabolic activity and blood supply. In summary, theragnostic is an emerging field that holds promise for improving the diagnosis and treatment of HCC. By combining diagnostic and therapeutic modalities into a single system, theragnostic can help guide personalized treatment decisions and improve patient outcomes.

【 授权许可】

Unknown   
© 2023 Nyakale, Aldous, Gutta, Khuzwayo, Harry and Sathekge.